转移性前列腺癌随机分配至根治性前列腺切除术或标准治疗的可行性
这项在比利时六家中心开展的II期、多中心、前瞻性、随机、开放标签可行性试验,于2018年8月至2024年8月筛查新诊断转移性前列腺癌患者,计划随机86例至减瘤性根治性前列腺切除术联合全身标准治疗或单纯标准治疗。共筛查325例,170例(52%)符合条件,最终43例随机,随机化率25%(43/170),低于预期,主要障碍为手术适格性有限和患者拒绝。
要点
- 新诊断转移性前列腺癌患者中仅52%(170/325)符合随机条件。
- 符合条件者中75%(127/170)被排除,主因患者拒绝(68%)和参与竞争研究(21%)。
- 最终随机化率仅25%(43/170),低于预期,限制试验可行性。
核心结论
- 在新诊断转移性前列腺癌患者中,随机分配至根治性前列腺切除术联合标准治疗或单纯标准治疗具有挑战性,主要障碍为手术适格性有限和患者拒绝。
研究设计与样本
- II期、多中心、前瞻性、随机、开放标签可行性试验,在比利时六家中心于2018年8月至2024年8月筛查新诊断转移性前列腺癌患者。
- 计划随机86例至减瘤性根治性前列腺切除术加盆腔淋巴结清扫联合全身标准治疗或单纯标准治疗(低瘤负荷疾病可包括放疗)。
- 入组条件包括ECOG体能状态评分0-1且被认为适合局部治疗。
- 主要终点为随机化可行性,以随机化率(随机例数/符合条件例数)评估。
主要发现
- 共筛查325例新诊断转移性前列腺癌患者,170例(52%)符合条件。
- 不符合条件的主要原因包括不可切除肿瘤(42% [65/155])和手术适格性不足(37% [58/155])。
- 符合条件患者中75%(127/170)被排除,主要因患者拒绝(68% [86/127])和参与竞争研究(21% [27/127])。
- 共43例随机:21例至减瘤性根治性前列腺切除术组,22例至标准治疗组,随机化率25%(43/170)。
关键数值与推荐
- 符合条件的患者需ECOG体能状态评分为0-1且被认为适合局部治疗。
- 随机化率定义为随机例数除以符合条件例数。
临床怎么用
- 在新诊断转移性前列腺癌患者中开展根治性前列腺切除术随机试验时,需考虑手术适格性筛选和患者拒绝对招募的影响。
- 可考虑针对性招募策略或替代试验设计以提高可行性。
局限性
- 随机化率低于预期,限制本试验背景下的可行性。
- 主要招募障碍包括手术适格性有限和患者拒绝。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the feasibility of randomising patients with newly diagnosed metastatic prostate cancer (mPCa) to cytoreductive radical prostatectomy (cRP) plus systemic standard of care (SOC) vs SOC alone in Belgian centres. PATIENTS AND METHODS: This is a phase II, multicentre, prospective, randomised, open-label feasibility trial. Patients with newly diagnosed mPCa were screened across six centres from August 2018 to August 2024. The aim was to randomise 86 patients to either cRP with pelvic lymphadenectomy plus systemic SOC or SOC alone (including radiotherapy in low-volume disease). Eligible patients had an Eastern Cooperative Oncology Group Performance Status of 0-1 and were considered suitable candidates for local treatment. The primary endpoint was the feasibility of randomisation, assessed by the randomisation rate (randomised/eligible). RESULTS: A total of 325 patients with newly diagnosed mPCa were screened, of whom 170 (52%) were eligible. The main reasons for ineligibility included unresectable tumours (42% [65/155]) and inadequate surgical fitness (37% [58/155]). Among eligible patients, 75% were excluded (127/170), mostly due to patient refusal (68% [86/127]) and inclusion in competing studies (21% [27/127]). A total of 43 patients were randomised: 21 to cRP and 22 to SOC, yielding a randomisation rate of 25% (43/170). Randomisation rates were lower than anticipated, limiting feasibility in the present trial setting. CONCLUSION: Randomising men with newly diagnosed mPCa to RP plus SOC vs SOC alone proved challenging in this Belgian trial. Major barriers to recruitment included limited surgical eligibility and patient refusal. Targeted recruitment strategies or alternative trial designs should be considered.
引用
- Van den Eynde L, Ost P, Verla W, et al. Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer. BJU Int. 2025. PMID: 40974177. doi:10.1111/bju.70006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。